comparemela.com

Henryj Fuchs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Weiss Asset Management LP Makes New Investment in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)

Weiss Asset Management LP Makes New Investment in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

BioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage from Analysts at Evercore ISI

Evercore ISI initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a research note released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $113.00 price objective on the biotechnology company’s stock. A number of other research analysts have also recently issued reports on BMRN. Piper Sandler […]

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Increased to $110 00 by Analysts at Wells Fargo & Company

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $100.00 to $110.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would suggest a potential […]

Jennison Associates LLC Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)

Jennison Associates LLC Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

BioMarin Pharmaceutical s (BMRN) Overweight Rating Reaffirmed at Cantor Fitzgerald

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 34.47% from the stock’s previous close. Several […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.